A Live-Attenuated HSV-2 ICP0− Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine
Mice were treated with 2 mg medoxyprogesterone 7 and 3 days prior to vaginal HSV-2 challenge . On Day 56 p.i., HSV-2 0ΔNLS- and MS-immunized mice were challenged with 500,000 pfu per vagina of HSV-2 MS. (A) HSV-2 shedding from the vagina between Days 2 and 6 post-challenge in naïve mice (n = 10) versus mice inoculated in the rear footpads with HSV-2 MS (n = 5) or HSV-2 0ΔNLS (n = 5). (B) HSV-2 shedding from the vagina of naïve mice versus mice inoculated in the eyes, nose, or vagina with HSV-2 0ΔNLS (n = 5 per group). In panels A and B, a single asterisk (*) denotes a probability, p, <0.05 and a double asterisk (**) denotes p<0.001 that HSV-2 shedding was equivalent to naïve controls on that day, as determined by one-way ANOVA and Tukey's post hoc t-test. (C) Survival frequency of naïve mice (n = 10) versus immunized mice (n = 5 per group) after HSV-2 challenge of the vagina. A double asterisk (**) denotes p<0.001 that survival frequency was equivalent to naïve mice.